Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE VALERATE versus M PREDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE VALERATE versus M PREDROL.
HYDROCORTISONE VALERATE vs M-PREDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Methylprednisolone is a glucocorticoid receptor agonist. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, chemokines, and adhesion molecules. It also inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Apply a thin film to affected area twice daily. Topical use only.
4 to 48 mg/day orally or intramuscularly in divided doses every 12 hours; for acute conditions, up to 120 mg/day intravenously in divided doses every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity)
Terminal elimination half-life: 2–4 hours. Clinical context: shorter than other corticosteroids; requires multiple daily doses for sustained anti-inflammatory effect.
Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites)
Primarily hepatic metabolism; <20% excreted unchanged in urine. Negligible biliary/fecal elimination.
Category D/X
Category C
Corticosteroid
Corticosteroid